Emanuel Della-Torre
Vita-Salute San Raffaele University
Internal medicineSurgeryPathologyCytotoxic T cellAntibodyNaive B cellImmunologyBiopsyTocilizumabPneumoniaSarilumabMavrilimumabDiseaseMEDLINEIgG4-related diseaseFibrosisRituximabAnakinraMedicineGastroenterology
72Publications
25H-index
2,713Citations
Publications 67
Newest
#1Giuseppe A. Ramirez (UniSR: Vita-Salute San Raffaele University)H-Index: 17
#2Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 25
Last. Mona-Rita Yacoub (UniSR: Vita-Salute San Raffaele University)H-Index: 12
view all 7 authors...
Source
#1Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 25
#2Marco Lanzillotta (UniSR: Vita-Salute San Raffaele University)H-Index: 14
Last. Lorenzo Dagna (UniSR: Vita-Salute San Raffaele University)H-Index: 33
view all 8 authors...
ABSTRACT Background The 2019 ACR/EULAR Classification Criteria for IgG4-related disease (IgG4-RD) represent a fundamental tool for patient enrollment in research studies and in clinical trials but their usefulness in daily clinical practice remains unknown. Objective To validate the 2019 ACR/EULAR Classification Criteria for IgG4-RD in a real-life setting and to anticipate their utility for orienting disease diagnosis and patient management. Methods Four experts were asked to classify 200 patien...
Source
#1Gaia Mancuso (UniSR: Vita-Salute San Raffaele University)H-Index: 3
#2Tatiana JofraH-Index: 9
Last. Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 25
view all 9 authors...
Source
#1Marco Lanzillotta (UniSR: Vita-Salute San Raffaele University)H-Index: 14
#2Andreu Fernández-Codina (UWO: University of Western Ontario)H-Index: 9
Last. Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 25
view all 7 authors...
INTRODUCTION Awareness of IgG4-related disease (IgG4-RD) is increasing worldwide and specialists are now familiar with most of its clinical manifestations and mimickers. IgG4-RD promptly responds to glucocorticoids and repeated courses are typically used to induce and maintain remission because the disease relapses in most patients. If left untreated it can lead to organ dysfunction, organ failure and death. Advancement in our understanding of IgG4-RD pathogenesis is leading to the identificatio...
Source
#1Marco Lanzillotta (UniSR: Vita-Salute San Raffaele University)H-Index: 14
#2Miriam Sant'Angelo (UniSR: Vita-Salute San Raffaele University)
Last. Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 25
view all 6 authors...
Source
#1Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 25
#2Marco Lanzillotta (UniSR: Vita-Salute San Raffaele University)H-Index: 14
Last. Lorenzo Dagna (UniSR: Vita-Salute San Raffaele University)H-Index: 33
view all 8 authors...
OBJECTIVE Rituximab is increasingly used in IgG4-related disease (IgG4-RD) but high costs limit its wide off-label administration. European and US regulatory agencies have recently approved rituximab biosimilars for the treatment of different rheumatologic and hematological conditions. No data are available, yet, on the efficacy and safety of rituximab biosimilars for the treatment of IgG4-RD. Scope of the present work is to evaluate the efficacy and safety of the rituximab biosimilar CT-P10 (RT...
1 CitationsSource
#1Lucrezia Rovati (UniSR: Vita-Salute San Raffaele University)H-Index: 6
#2Naoki Kaneko (Ragon Institute of MGH, MIT and Harvard)H-Index: 10
Last. Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 25
view all 13 authors...
OBJECTIVES IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory disorder characterized by a dysregulated resolution of inflammation and wound healing response that might develop after an apoptotic insult induced by cytotoxic T lymphocytes (CTLs). Mer receptor tyrosine kinase (MerTK) and its ligand Protein S (ProS1) have a pivotal role in the resolution of inflammation, being implicated in the clearance of apoptotic cells, quenching of the immune response and development of tissue fibr...
Source
#1Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 25
#2Gaia Mancuso (UniSR: Vita-Salute San Raffaele University)H-Index: 3
Last. Lorenzo Dagna (UniSR: Vita-Salute San Raffaele University)H-Index: 33
view all 8 authors...
OBJECTIVE Immunoglobulin G4-related disease (IgG4-RD) is considered a chronic condition with insidious presentation, but clinical experience suggests that disease onset prompts admission to the emergency department (ED) in a sizeable proportion of patients. We assessed the prevalence of acute manifestations associated with IgG4-RD onset requiring referral to the ED. METHOD We revised our database and identified patients admitted to the ED because of symptoms latterly attributed to IgG4-RD onset ...
2 CitationsSource
#1Cory A. Perugino (Harvard University)H-Index: 13
#2Naoki Kaneko (Kyushu University)H-Index: 10
Last. Shiv Pillai (Ragon Institute of MGH, MIT and Harvard)H-Index: 50
view all 28 authors...
Abstract Background IgG4-related disease (IgG4-RD) is an immune-mediated fibrotic disorder that has been linked to CD4+ cytotoxic T lymphocytes (CD4+CTLs). The effector phenotype of CD4+CTLs, the relevance of both CD8+ cytotoxic T lymphocytes (CD8+CTLs) and of apoptotic cell death remain undefined in IgG4-RD. Objective The goals of this study were to define CD4+CTL heterogeneity, characterize the CD8+CTL response in the blood and in lesions, and determine whether enhanced apoptosis may contribut...
9 CitationsSource
#1Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 25
#2Marco Lanzillotta (UniSR: Vita-Salute San Raffaele University)H-Index: 14
Last. Lorenzo Dagna (UniSR: Vita-Salute San Raffaele University)H-Index: 33
view all 16 authors...
Background. Restraining maladaptive inflammation is considered a rationale strategy to treat severe COVID-19 but available studies with selective inhibitors of pro-inflammatory cytokines have not provided unequivocal evidence of survival advantage. Late administration is commonly regarded as a major cause of treatment failure but the optimal timing for anti-cytokine therapy initiation in COVID-19 patients has never been clearly established. Objectives. To identify a window of therapeutic opportu...
Source